Merck to acquire Prometheus Biosciences for $10.8B

Shares of Prometheus Biosciences soared 70% in premarket trading on Monday after Merck & Co. announced that it would acquire the company in a $10.8 billion deal. All the shares of Prometheus Biosciences will be acquired by a subsidiary of Merck for $200 per share. The acquisition is subject to…#merckco #merck #prometheus #robertdavis #keytruda #sandiego #crohn #imagobiosciences
Source: Reuters: Health - Category: Consumer Health News Source Type: news